Teva Pharmaceutical Industries (TEVA) Interest Expenses (2009 - 2025)

Teva Pharmaceutical Industries' Interest Expenses history runs 16 years deep, the most recent figure standing at $397.0 million for Q4 2025.

• Quarterly Interest Expenses fell 80.32% year-over-year to $397.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $397.0 million (down 80.32% YoY) and the FY2025 annual result came in at $2.3 billion, up 16.11% from the prior year.
• Interest Expenses was $397.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $2.0 billion in the prior quarter.
• Across five years, Interest Expenses topped out at $3.1 billion in Q4 2022 and bottomed at $397.0 million in Q4 2025.
• A 5-year average of $2.2 billion and a median of $2.7 billion in 2021 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses gained 12.82% — and 2025, when it slumped 80.32%.
• Teva Pharmaceutical Industries' Interest Expenses stood at $2.7 billion in 2021, then advanced by 12.82% to $3.1 billion in 2022, then decreased by 2.05% to $3.0 billion in 2023, then tumbled by 32.97% to $2.0 billion in 2024, then sank by 80.32% to $397.0 million in 2025.
• Business Quant data shows TEVA's Interest Expenses at $397.0 million in Q4 2025, $2.0 billion in Q4 2024, and $3.0 billion in Q4 2023.